Base de dados : MEDLINE
Pesquisa : C04.697.650.895 [Categoria DeCS]
Referências encontradas : 3221 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 323 ir para página                         

  1 / 3221 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29400040
[Au] Autor:Lechien JR; Doyen J; Deleuze M; Khalife M; Saussez S
[Ti] Título:Giant metastasis invading pharyngeal wall, pterygo­maxillary space, submaxillary and parotid glands.
[So] Source:Rev Laryngol Otol Rhinol (Bord);136(4):167-8, 2015.
[Is] ISSN:0035-1334
[Cp] País de publicação:France
[La] Idioma:eng
[Mh] Termos MeSH primário: Carcinoma de Células Escamosas/patologia
Neoplasias de Cabeça e Pescoço/patologia
Neoplasias Primárias Desconhecidas/patologia
Faringe/patologia
Neoplasias das Glândulas Salivares/secundário
[Mh] Termos MeSH secundário: Feminino
Seres Humanos
Meia-Idade
Invasividade Neoplásica
Glândula Parótida/patologia
Glândula Submandibular/patologia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180308
[Lr] Data última revisão:
180308
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180206
[St] Status:MEDLINE


  2 / 3221 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29361629
[Au] Autor:Yamada M; Uchiyama K; Tashiro M
[Ad] Endereço:Dept. of Dentistry and Oral Surgery, Tochigi Medical Center.
[Ti] Título:[A Case of Cervical Lymph Node Metastasis from an Unknown Primary Cancer Controlled with Immunotherapy, Chemotherapy, and Surgery].
[So] Source:Gan To Kagaku Ryoho;44(13):2113-2116, 2017 Dec.
[Is] ISSN:0385-0684
[Cp] País de publicação:Japan
[La] Idioma:jpn
[Ab] Resumo:We present a case of cervical lymph node metastasis from an unknown primary cancer that was controlled with immunotherapy, chemotherapy, and surgery. The patient, a 61-year-old man, was referred to our department for treatment of a lesion in the left cervical lateral area. At the initial visit, the mass was covered by reddened skin and was elastic, hard, and immobile on palpation. The presence of a malignant disease such as malignant lymphoma or lymphadenitis because of infection by tubercle bacillus or Epstein-Barr virus was suspected on the basis of the clinical and magnetic resonance imaging findings. Biopsy and resection of the cervical mass was performed under general anesthesia. Because the pathological diagnosis during surgery indicated squamous cell carcinoma, the surgical approach was changed to neck dissection. Head, neck, and thoracic computed tomography and other examinations were performed to locate the primary cancer, but its origin remained unknown. Postoperative therapy consisted of chemotherapy and immunotherapy. The patient has been followed up for 4 years and 10 months without any evidence of recurrence.
[Mh] Termos MeSH primário: Antineoplásicos/uso terapêutico
Imunoterapia
Neoplasias Primárias Desconhecidas/terapia
[Mh] Termos MeSH secundário: Seres Humanos
Metástase Linfática
Imagem por Ressonância Magnética
Masculino
Meia-Idade
Esvaziamento Cervical
Neoplasias Primárias Desconhecidas/diagnóstico por imagem
Neoplasias Primárias Desconhecidas/imunologia
Neoplasias Primárias Desconhecidas/patologia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antineoplastic Agents)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180302
[Lr] Data última revisão:
180302
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180124
[St] Status:MEDLINE


  3 / 3221 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29275831
[Au] Autor:Troussier I; Klausner G; Morinière S; Blais E; Jean-Christophe Faivre; Champion A; Geoffrois L; Pflumio C; Babin E; Maingon P; Thariat J
[Ad] Endereço:CHRU Pitié-Salpêtrière, radiothérapie, 47-83, boulevard de l'Hôpital, 75013 Paris, France.
[Ti] Título:[Advances in the management of cervical lymphadenopathies of unknown primary: advances in diagnostic imaging and surgical modalities and new international staging system].
[Ti] Título:Évolutions dans la prise en charge des métastases ganglionnaires cervicales sans cancer primitif retrouvé : avancées diagnostiques et nouvelle classification TNM..
[So] Source:Bull Cancer;105(2):181-192, 2018 Feb.
[Is] ISSN:1769-6917
[Cp] País de publicação:France
[La] Idioma:fre
[Ab] Resumo:INTRODUCTION: Cervical lymphadenopathies of unknown primary represent 3 % of head and neck cancers. Their diagnostic work up has largely changed in recent years. This review provides an update on diagnostic developments and their potential therapeutic impact. MATERIALS AND METHODS: This is a systematic review of the literature. RESULTS: In recent years, changes in epidemiology-based prognostic factors such as human papilloma virus (HPV) cancers, advances in imaging and minimally invasive surgery have been integrated in the management of cervical lymphadenopathies of unknown primary. In particular, systematic use of PET scanner and increasing practice of robotic or laser surgery have contributed to increasing detection rate of primary cancers. These allow more adapted and personalized treatments. The impact of changes in the eighth TNM staging system is discussed. CONCLUSION: The management of cervical lymphadenopathies of unknown primary cancer has changed significantly in the last 10 years. On the other hand, practice changes will have to be assessed.
[Mh] Termos MeSH primário: Carcinoma/diagnóstico por imagem
Carcinoma/terapia
Metástase Linfática/diagnóstico por imagem
Neoplasias Primárias Desconhecidas/diagnóstico por imagem
Neoplasias Primárias Desconhecidas/terapia
[Mh] Termos MeSH secundário: Antineoplásicos/uso terapêutico
Biópsia por Agulha Fina
Carcinoma/secundário
Carcinoma de Células Escamosas/diagnóstico
Carcinoma de Células Escamosas/patologia
Carcinoma de Células Escamosas/terapia
Carcinoma de Células Escamosas/virologia
Quimiorradioterapia
Terapia Combinada/métodos
Neoplasias de Cabeça e Pescoço/diagnóstico por imagem
Neoplasias de Cabeça e Pescoço/patologia
Neoplasias de Cabeça e Pescoço/terapia
Neoplasias de Cabeça e Pescoço/virologia
Seres Humanos
Metástase Linfática/patologia
Pescoço
Estadiamento de Neoplasias/métodos
Neoplasias Primárias Desconhecidas/patologia
Papillomaviridae/isolamento & purificação
Tonsilectomia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antineoplastic Agents)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180228
[Lr] Data última revisão:
180228
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171226
[St] Status:MEDLINE


  4 / 3221 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29443782
[Au] Autor:Yamasaki M; Funaishi K; Saito N; Sakano A; Fujihara M; Daido W; Ishiyama S; Deguchi N; Taniwaki M; Ohashi N; Hattori N
[Ad] Endereço:Department of Respiratory Disease, Hiroshima Red Cross Hospital & Atomic Bomb Survivors Hospital, Naka-ku.
[Ti] Título:Putative lung adenocarcinoma with epidermal growth factor receptor mutation presenting as carcinoma of unknown primary site: A case report.
[So] Source:Medicine (Baltimore);97(7):e9942, 2018 Feb.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: Only a few cases of putative lung adenocarcinoma presenting as carcinoma of unknown primary site (CUP) with epidermal growth factor receptor (EGFR) mutation have been reported, and the efficacy of EGFR-tyrosine kinase inhibitors (TKIs) for these cases is unclear. PATIENT CONCERNS AND DIAGNOSES: A 67-year-old man complained of paresis of the right lower extremity, dysarthria, and memory disturbance. Computed tomography and magnetic resonance imaging showed multiple brain tumors with brain edema and swelling of the left supraclavicular, mediastinal, and upper abdominal lymph nodes. Moreover, a metastatic duodenal tumor was detected via upper gastrointestinal endoscopy examination. The biopsy specimen of the lesion was examined and was diagnosed as adenocarcinoma with CK7 and TTF-1 positivity. Finally, the case was diagnosed as EGFR mutation-positive putative lung adenocarcinoma presenting as CUP. INTERVENTIONS AND OUTCOMES: Oral erlotinib, an EGFR-TKI, was administered at 150 mg daily. Five weeks later, the brain lesions and several swollen lymph nodes showed marked improvement, and the symptoms of the patient also improved. Three months later, the duodenal lesion was undetected on upper gastrointestinal endoscopy. After an 8-month follow-up, the patient was well with no disease progression. LESSONS: Putative lung adenocarcinoma presenting as CUP may have EGFR mutation, and EGFR-TKI therapy may be effective for such malignancy.
[Mh] Termos MeSH primário: Adenocarcinoma/genética
Neoplasias Pulmonares/genética
Mutação
Neoplasias Primárias Desconhecidas
Receptor do Fator de Crescimento Epidérmico/genética
[Mh] Termos MeSH secundário: Adenocarcinoma/tratamento farmacológico
Idoso
Antineoplásicos/uso terapêutico
Cloridrato de Erlotinib/uso terapêutico
Seres Humanos
Neoplasias Pulmonares/tratamento farmacológico
Masculino
Inibidores de Proteínas Quinases/uso terapêutico
Receptor do Fator de Crescimento Epidérmico/antagonistas & inibidores
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antineoplastic Agents); 0 (Protein Kinase Inhibitors); DA87705X9K (Erlotinib Hydrochloride); EC 2.7.10.1 (Receptor, Epidermal Growth Factor)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180220
[Lr] Data última revisão:
180220
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180215
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009942


  5 / 3221 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29390502
[Au] Autor:Xu R; Li J; Zhang Y; Jing H; Zhu Y
[Ad] Endereço:Medicine and Life Sciences College of Shandong Academy of Medical Sciences, University of Jinan.
[Ti] Título:Male occult breast cancer with axillary lymph node metastasis as the first manifestation: A case report and literature review.
[So] Source:Medicine (Baltimore);96(51):e9312, 2017 Dec.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: Occult breast cancer (OBC) is extremely rare in males with neither symptoms in the breast nor abnormalities upon imaging examination. PATIENT CONCERNS: This current case report presents a young male patient who was diagnosed with male OBC first manifesting as axillary lymph node metastasis. The physical and imaging examination showed no primary lesions in either breasts or in other organs. DIAGNOSES: The pathological results revealed infiltrating ductal carcinoma in the axillary lymph nodes. Immunohistochemical (IHC) staining was negative for estrogen receptor (ER), progesterone receptor (PR), cytokeratin (CK)20 and thyroid transcription factor-1 (TTF-1), positive for CK7, gross cystic disease fluid protein-15 (GCDFP-15), epithelial membrane antigen (EMA) and carcinoembryonic antigen (CEA), and suspicious positive for human epidermal receptor-2 (Her-2). On basis of IHC markers, particularly such as CK7, CK20 and GCDFP-15, and eliminating other malignancies, male OBC was identified in spite of negativity for hormone receptors. INTERVENTIONS: The patient underwent left axillary lymph node dissection (ALND) but not mastectomy. After the surgery, the patient subsequently underwent chemotherapy and radiotherapy. OUTCOMES: The patient is currently being followed up without any signs of recurrence. LESSONS: Carefully imaging examination and pathological analysis were particularly essential in the diagnosis of male OBC. The guidelines for managing male OBC default to those of female OBC and male breast cancer.
[Mh] Termos MeSH primário: Axila
Neoplasias da Mama Masculina/patologia
Carcinoma Ductal de Mama/patologia
Metástase Linfática
Neoplasias Primárias Desconhecidas/patologia
[Mh] Termos MeSH secundário: Adulto
Axila/diagnóstico por imagem
Axila/patologia
Neoplasias da Mama Masculina/diagnóstico por imagem
Neoplasias da Mama Masculina/terapia
Carcinoma Ductal de Mama/diagnóstico por imagem
Carcinoma Ductal de Mama/terapia
Seres Humanos
Excisão de Linfonodo
Masculino
Neoplasias Primárias Desconhecidas/diagnóstico por imagem
Neoplasias Primárias Desconhecidas/terapia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180220
[Lr] Data última revisão:
180220
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180203
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009312


  6 / 3221 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29365416
[Au] Autor:Zhang JJ; Yang XT; Du XS; Zhang JX; Hou LN; Niu JL
[Ad] Endereço:Department of MR&CT, Shanxi cancer hospital, Taiyuan 030013, China.
[Ti] Título:[MRI findings and pathological features of occult breast cancer].
[So] Source:Zhonghua Zhong Liu Za Zhi;40(1):40-45, 2018 Jan 23.
[Is] ISSN:0253-3766
[Cp] País de publicação:China
[La] Idioma:chi
[Ab] Resumo:To investigate the magnetic resonance imaging (MRI) findings and clinicopathological features of primary lesions in patients with occult breast cancer (OBC). The imaging reports from the Breast Imaging Reporting and Data System in 2013 were retrospectively analyzed to investigate the morphology and the time signal intensity curve (TIC) of breast lesions in patients with OBC. The clinical and pathological characteristics of these patients were also included. A total of 34 patients were enrolled. Among these patients, 24 patients underwent modified radical mastectomy and 18 of them had primary breast carcinoma in pathological sections. MRI detected 17 cases of primary lesions, including six masse lesions with a diameter of 0.6-1.2 cm (average 0.9 cm), and 11 non-mass lesions with four linear distributions, three segmental distributions, three focal distributions, and one regions distribution. Five patients had TIC typeâ… primary lesions, ten had TIC type â…¡ primary lesions, and two had TIC type â…¢ primary lesions. Among all 34 cases, 23 of them had complete results of immunohistochemistry: 11 estrogen receptor (ER) positive lesions (47.8%), tenprogesterone receptor (PR) positive lesions (43.5%), seven human epidermal growth factor receptor 2 (HER-2) positive lesions (30.4%), and 20high expression(>14%) of Ki-67 (87.0%). The proportion of type luminal A was 4.3%, type luminal B was 43.5%, triple negative breast cancer (TNBC) was 30.4%, and HER-2 over expression accounted for 21.7%. The primary lesions of OBC usually manifested as small mass lesions, or focal, linear or segmental distribution of non-mass lesions. The positive rate of ER and PR was low, but the positive rate of HER-2 and the proliferation index of Ki-67 was high. Type luminal B is the most common molecular subtype.
[Mh] Termos MeSH primário: Neoplasias da Mama/patologia
[Mh] Termos MeSH secundário: Adulto
Mama/química
Mama/diagnóstico por imagem
Mama/patologia
Neoplasias da Mama/química
Neoplasias da Mama/diagnóstico por imagem
Neoplasias da Mama/cirurgia
Feminino
Seres Humanos
Imuno-Histoquímica
Antígeno Ki-67/análise
Imagem por Ressonância Magnética
Mastectomia Radical Modificada
Meia-Idade
Neoplasias Primárias Desconhecidas/química
Neoplasias Primárias Desconhecidas/diagnóstico por imagem
Neoplasias Primárias Desconhecidas/patologia
Neoplasias Primárias Desconhecidas/cirurgia
Receptor ErbB-2/análise
Receptores Estrogênicos/análise
Receptores de Progesterona/análise
Estudos Retrospectivos
Carga Tumoral
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Ki-67 Antigen); 0 (Receptors, Estrogen); 0 (Receptors, Progesterone); EC 2.7.10.1 (ERBB2 protein, human); EC 2.7.10.1 (Receptor, ErbB-2)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180212
[Lr] Data última revisão:
180212
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180125
[St] Status:MEDLINE
[do] DOI:10.3760/cma.j.issn.0253-3766.2018.01.007


  7 / 3221 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29369202
[Au] Autor:Ju Y; Tian D; Tan Y; Fu Z
[Ad] Endereço:Department of Pain Management, Shandong Provincial Hospital Affiliated to Shandong University, Shandong University, Shandong China.
[Ti] Título:Palliative care with cervical intrathecal infusion and external pump for a late-stage cancer patient with refractory pain: A case report.
[So] Source:Medicine (Baltimore);97(4):e9714, 2018 Jan.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: Intrathecal therapy, with a low complication rate, has become an alternative to standard pain management for treatment of neuropathic cancer pain. PATIENT CONCERNS: Here, we reported a late-stage cancer patient with intractable neuropathic pain in his right neck, shoulder, and upper limb. DIAGNOSES: The pain started 2 years ago when the patient was diagnosed as squamous cell carcinoma with metastasis to right supraclavicular lymph nodes. INTERVENTIONS: Cervical intrathecal infusion of morphine and bupivacaine with patient control analgesia by external pump was performed. The intrathecal catheter was located at the level of C6 vertebra. The initial concentration of bupivacaine and morphine were both 1 mg/mL with infusion rate of 0.3 mL/h and bolus of 0.3 mL. Subsequently, the concentrations increased to 2 mg/mL (bupivacaine) and 1.33 mg/mL (morphine), with infusion rate to 0.6 mL/h and bolus to 0.5 ml. OUTCOMES: The pain intensity decreased from numerical rating scale 6 to 7 to 2 to 3 at rest, and from 10 to 5 to 6 of breakthrough pain. LESSONS: In conclusion, cervical intrathecal infusion requires low concentration but high doses of bupivacaine and morphine, which is safe and effective in cancer patients with refractory pain and short life expectancy.
[Mh] Termos MeSH primário: Infusão Espinal/métodos
Neuralgia/tratamento farmacológico
Manejo da Dor/métodos
Dor Intratável/tratamento farmacológico
Cuidados Paliativos/métodos
[Mh] Termos MeSH secundário: Idoso
Analgesia Controlada pelo Paciente/métodos
Analgésicos Opioides/administração & dosagem
Anestésicos Locais/administração & dosagem
Bupivacaína/administração & dosagem
Carcinoma de Células Escamosas/complicações
Carcinoma de Células Escamosas/secundário
Vértebras Cervicais
Seres Humanos
Masculino
Morfina/administração & dosagem
Neoplasias Primárias Desconhecidas/complicações
Neuralgia/etiologia
Dor Intratável/etiologia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Analgesics, Opioid); 0 (Anesthetics, Local); 76I7G6D29C (Morphine); Y8335394RO (Bupivacaine)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180208
[Lr] Data última revisão:
180208
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180126
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009714


  8 / 3221 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29285946
[Au] Autor:Brooks D; Hughes P; Farrington C; Bath PA; McGregor M; Ahmed W; Noble B
[Ad] Endereço:c Chesterfield Royal Hospital NHS Foundation Trust , Chesterfield , UK.
[Ti] Título:Implementation of a metastatic malignancy of unknown primary origin service led by a palliative physician.
[So] Source:Hosp Pract (1995);46(1):37-42, 2018 Feb.
[Is] ISSN:2154-8331
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Cancer of unknown primary is the fourth most common cause of cancer death in the United Kingdom. National guidance in 2010 recommended the establishment of a dedicated unknown primary team to facilitate targeted investigation and symptom control. A service development project was undertaken to identify those affected by malignancy of unknown origin and institute a pathway for coordinating their care led by a palliative physician. METHOD: In order to describe the patient population and illness trajectory and to assess the effect of the new pathway on the clinical outcomes we used a retrospective and prospective comparative case notes survey to identify the pre- and post-pathway population. This took place in secondary care. Inclusion criteria were patients with metastatic disease with no known primary; exclusion criteria were where the site of metastasis was so suggestive of a primary that it would be managed as per that disease process. 88 patients were included. RESULTS: Mean age was 72.5 years. The mean survival time from presentation was 81.8 days. There was no difference pre or during pathway implementation in age, performance status or survival time. There was no reduction in the numbers referred for tumour directed therapy. There was a non-statistically significant reduction in the number who died in hospital during the pathway implementation. CONCLUSIONS: This study suggests having a metastatic malignancy of unknown primary origin service led by a palliative physician does not reduce the number referred for tumour directed therapy. It also adds evidence of the poor prognosis and thus the need for early palliative care input.
[Mh] Termos MeSH primário: Neoplasias Primárias Desconhecidas/mortalidade
Neoplasias Primárias Desconhecidas/terapia
Cuidados Paliativos/organização & administração
Equipe de Assistência ao Paciente/organização & administração
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Feminino
Seres Humanos
Estimativa de Kaplan-Meier
Masculino
Meia-Idade
Prognóstico
Avaliação de Programas e Projetos de Saúde
Estudos Retrospectivos
Medicina Estatal
Reino Unido
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180205
[Lr] Data última revisão:
180205
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171230
[St] Status:MEDLINE
[do] DOI:10.1080/21548331.2018.1418140


  9 / 3221 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29298151
[Au] Autor:Atri D; Furfaro D; Dhaliwal G; Feingold KR; Manesh R
[Ad] Endereço:From the Department of Medicine, Johns Hopkins Hospital and Johns Hopkins University School of Medicine, Baltimore (D.A., D.F., R.M.); and the Department of Medicine, University of California, San Francisco, and the Medical Service, San Francisco Veterans Affairs Medical Center - both in San Francis
[Ti] Título:Going from A to Z.
[So] Source:N Engl J Med;378(1):73-79, 2018 01 04.
[Is] ISSN:1533-4406
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Diarreia/etiologia
Gastrinoma/diagnóstico
Neoplasias Hepáticas/secundário
Fígado/diagnóstico por imagem
Neoplasias Primárias Desconhecidas/diagnóstico
Síndrome de Zollinger-Ellison/diagnóstico
[Mh] Termos MeSH secundário: Abdome/diagnóstico por imagem
Dor Abdominal/etiologia
Idoso
Análise Química do Sangue
Doença Crônica
Diagnóstico Diferencial
Gastrinoma/complicações
Gastrinoma/diagnóstico por imagem
Seres Humanos
Fígado/patologia
Neoplasias Hepáticas/diagnóstico
Neoplasias Hepáticas/patologia
Imagem por Ressonância Magnética
Masculino
Neoplasias Primárias Desconhecidas/complicações
Policitemia/complicações
Tomografia Computadorizada com Tomografia por Emissão de Pósitrons
Síndrome de Zollinger-Ellison/complicações
[Pt] Tipo de publicação:CASE REPORTS; CLINICAL CONFERENCE; JOURNAL ARTICLE
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180118
[Lr] Data última revisão:
180118
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180104
[St] Status:MEDLINE


  10 / 3221 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28746931
[Au] Autor:Utter K; Goldman C; Weiss SA; Shapiro RL; Berman RS; Wilson MA; Pavlick AC; Osman I
[Ad] Endereço:The Ronald O. Perelman Department of Dermatology, New York University School of Medicine, New York, NY, USA.
[Ti] Título:Treatment Outcomes for Metastatic Melanoma of Unknown Primary in the New Era: A Single-Institution Study and Review of the Literature.
[So] Source:Oncology;93(4):249-258, 2017.
[Is] ISSN:1423-0232
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Metastatic melanoma of unknown primary (MUP) is uncommon, biologically ill defined, and clinically understudied. MUP outcomes are seldom reported in clinical trials. In this study, we analyze responses of MUP patients treated with systemic therapy in an attempt to inform treatment guidelines for this unique population. METHODS: New York University (NYU)'s prospective melanoma database was searched for MUP patients treated with systemic therapy. PubMed and Google Scholar were searched for MUP patients treated with immunotherapy or targeted therapy reported in the literature, and their response and survival data were compared to the MUP patient data from NYU. Both groups' response data were compared to those reported for melanoma of known primary (MKP). RESULTS: The MUP patients treated at NYU had better outcomes on immunotherapy but worse on targeted therapy than the MUP patients in the literature. The NYU MUP patients and those in the literature had worse outcomes than the majority-MKP populations in 10 clinical trial reports. CONCLUSIONS: Our study suggests that MUP patients might have poorer outcomes on systemic therapy as compared to MKP patients. Our cohort was small and limited data were available, highlighting the need for increased reporting of MUP outcomes and multi-institutional efforts to understand the mechanism behind the observed differences.
[Mh] Termos MeSH primário: Melanoma/secundário
Neoplasias Primárias Desconhecidas/patologia
Neoplasias Cutâneas/secundário
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Feminino
Seguimentos
Seres Humanos
Masculino
Melanoma/mortalidade
Melanoma/terapia
Meia-Idade
Terapia de Alvo Molecular
Neoplasias Primárias Desconhecidas/mortalidade
Neoplasias Primárias Desconhecidas/terapia
New York/epidemiologia
Prognóstico
Estudos Prospectivos
Neoplasias Cutâneas/mortalidade
Neoplasias Cutâneas/terapia
Taxa de Sobrevida
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180115
[Lr] Data última revisão:
180115
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170727
[St] Status:MEDLINE
[do] DOI:10.1159/000478050



página 1 de 323 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde